AbbVie has signed a deal with Teneobio to develop a B-cell maturation antigen (BCMA)-targeting bispecific antibody for multiple myeloma.Original Article
You may also like
Exploring 3D Printing for Solid Dosage Drugs
Control Strategies and Method Development for...
CPHI Milan 2024: Fill/Finish and Sustainability
CPHI Milan 2024: Industry Trends Impacting Oral Solid...
CPHI Milan 2024: Evolution of Coating Design
Improving the Sustainability of API Manufacturing with...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.